Premium
Oral contraceptives and prognosis of breast cancer in women aged 35 to 50
Author(s) -
Rosner Dutzu H.,
Joy Judyann V.,
Lane Warren W.
Publication year - 1985
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930300114
Subject(s) - medicine , breast cancer , gynecology , cancer , oncology
Among 193 breast cancer patients aged 35–50 years, there was no appreciable difference in the extent of disease at diagnosis between 53 oral contraceptive (OC) users and 140 OC non‐users. There was no overall significant difference between OC users and non‐users for either the disease‐free interval (P=.81), metastatic period (P=.41), or survival (P=.79), either alone or when adjusted for stage or family history. The survival rate of OC users of more than 2 years was similar to the survival rate of those of shorter duration ( P=.36). Patients who began the use of OC 10 years or more before diagnosis showed no statistical difference from those beginning more recently (P=.69). Recent OC users within a year of diagnosis had a survival rate similar to that of other users who stopped the pills at least 1 year prior to diagnosis (P=.14). Our data suggest no adverse effects of OC use on the prognosis of breast cancer, regardless of duration of use, latency or recency period.